Quince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) has received an average recommendation of "Buy" from the six analysts that are presently covering the company, MarketBeat.com reports. Four analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $9.50.
QNCX has been the topic of a number of recent analyst reports. D. Boral Capital reiterated a "buy" rating and set a $12.00 target price on shares of Quince Therapeutics in a research note on Thursday, January 2nd. Maxim Group assumed coverage on shares of Quince Therapeutics in a research report on Thursday, November 7th. They issued a "buy" rating and a $6.00 price objective on the stock. RODMAN&RENSHAW upgraded shares of Quince Therapeutics to a "strong-buy" rating in a research note on Tuesday, October 29th. Brookline Capital Management began coverage on Quince Therapeutics in a report on Wednesday, December 18th. They set a "buy" rating and a $9.00 price objective for the company. Finally, EF Hutton Acquisition Co. I raised Quince Therapeutics to a "strong-buy" rating in a report on Tuesday, October 22nd.
Check Out Our Latest Report on QNCX
Institutional Trading of Quince Therapeutics
An institutional investor recently bought a new position in Quince Therapeutics stock. Scharf Investments LLC bought a new stake in Quince Therapeutics, Inc. (NASDAQ:QNCX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 91,061 shares of the company's stock, valued at approximately $170,000. Scharf Investments LLC owned 0.21% of Quince Therapeutics as of its most recent filing with the Securities & Exchange Commission. 30.75% of the stock is currently owned by institutional investors and hedge funds.
Quince Therapeutics Stock Up 8.2 %
QNCX traded up $0.13 during midday trading on Monday, reaching $1.72. 154,314 shares of the company were exchanged, compared to its average volume of 145,957. Quince Therapeutics has a one year low of $0.51 and a one year high of $2.45. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53. The company's fifty day moving average price is $1.86 and its 200 day moving average price is $1.22. The company has a market cap of $75.68 million, a price-to-earnings ratio of -1.39 and a beta of 0.64.
About Quince Therapeutics
(
Get Free ReportQuince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Read More
Before you consider Quince Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quince Therapeutics wasn't on the list.
While Quince Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
